

Nifty Next 100 Portfolio

July 2022



**ADITYA BIRLA
CAPITAL**


PROTECTING INVESTING FINANCING ADVISING

What is Nifty Next 100?

- ✓ Nifty Next 100 comprises of stocks arrived at after excluding the Nifty 50 members from the Top 150 stocks by market cap.

NIFTY Next 100 stocks captures the sweet spot between Large Caps and Mid Caps

- ✓ Perfect balance of Growth & Quality.
- ✓ Characterized by years of Strong Performance and Growth.
- ✓ Well diversified across secular sectors, with less exposure to commodity cyclicals.
- ✓ Less volatile than Mid and Small Cap Indices and offers higher growth potential than top 50 stocks.
- ✓ Captures 17% of the free float market cap of the top 500 stocks, with high levels of liquidity.
- ✓ Long term outperformance of NIFTY Next 100 stocks over NIFTY 50 without taking undue risk of Small Caps.



Nifty Next 100: Captures Positives of Large Caps and Mid Caps

Index	Beta	Volatility
Nifty 50 Index	1	13.10%
Nifty Next 100	1.01	13.80%
Nifty Midcap Index	1.08	17.70%
Nifty Smallcap Index	1.17	17.20%

Large Caps

Mid Caps


**NIFTY
Next
100**

- Quality
- Long track record
- Established business models
- Higher Liquidity
- Strong Corporate Governance

- Higher Growth Potential
- Participate in Emerging Sectors
- Higher Entrepreneurial Spirit
- Higher Risk/Reward ratio


Market Cap Bias	Free float M.Cap	No. of stocks
Large Cap	58.85%	52%
Mid Cap	41.15%	48%

Nifty Next 100: Performance matters!



- ✓ Next 100 stocks have outperformed the Top 50 stocks (Nifty Index) by 5% CAGR since January 2003, despite last 2.5 years underperformance.
- ✓ Next 100 stocks have exhibited lower volatility versus the small and mid cap stocks, but still outperformed the Nifty Midcap and Smallcap Indices over longer period.

Nifty Next 100: Performance matters!



Nifty Next 100 Outperformance (O/P)			
Years	O/P	Next 1 year	Next 3 year Absolute O/P
CY06	-9%	31%	58%
CY08	-10%	36%	29%
CY13	-11%	22%	40%
CY18-CY20	-26%	?	?
CY21 YTD	10%	?	?

- Next 100 stocks have outperformed the Top 50 stocks (Nifty Index) 60% of time from CY03 to Dec'20
- Next 100 stocks have outperformed Nifty Index strongly after periods of underperformance as can be seen in the table
- The degree of outperformance in upcycle tends to be much higher than the degree of underperformance in downcycles


Nifty Next 100 Portfolio Offering



NIFTY Next 100 Portfolio is a diversified portfolio which would be primarily invested in Large and Mid Caps.

- ✓ The weight of Nifty 50 Stocks would be less than 30%
- ✓ Focus would be on top 150 stocks (excluding NIFTY 50), constituting around 70% of the portfolio
- ✓ Objective is to deliver returns higher than Large Cap Fund, without taking undue risk/volatility of small mid caps
- ✓ Well diversified across secular sectors, with less exposure to commodity cyclicals. Can take high conviction sector calls, compared to benchmark, if required.
- ✓ Stock limit: 10% at cost

Portfolio Construct			
Category	Weight	Rationale	Stocks
Next 100 stocks by Market cap	65%-100%	Diversified set of stocks balancing Quality, Growth & Safety	Kansai Nerolac, Apollo Hospitals, Honeywell Automation
High conviction ideas outside Next 100 stocks	0%-35%	Leverage opportunities in select high growth stocks across Nifty 50 /Small caps	Bajaj Finserv, ABFRL




Science (Quantitative factors)

- Strong balance sheets
- Good capital allocation track record
- High return on capital over a longer time frame
- Piotroski score, ROE, Leverage check


Art (Qualitative factors)

- High corporate governance
- Established business model
- Prominent market share
- Skilled management
- Long term market opportunity

Bottom up stock picking approach



- ✓ High P Score (>6) companies outperform the BSE 200 Index by 3% CAGR since CY2006.
- ✓ Till 2016, the outperformance was higher at 7.5%, however, in the last 2 years, stock returns have not moved in line with fundamentals given the sharp divergence in the market. We expect the trend to normalise over the next few years



- ✓ High ROE companies which show improvement outperform the BSE 200 index by 6.7% CAGR since CY06.
- ✓ Till 2016, the last 10 year outperformance was even higher at 9.2%.

P-Score: Captures Fundamentals


$$P_SCORE = F_ROA + F_DROA + F_CFO + F_ACCRUAL + F_DTURN + F_DMARGIN + F_DLEVER + F_DLIQUID + EQ_OFFER$$

No.	Ratios	Definition	Positive signal if
QUALITY			
PROFITABILITY			
1	Return on Assets (ROA)	Net Income/Total Assets	ROA>0
2	Cash flow from Operations (CFO)	Cash flow from Operations/Total Assets	CFO>0
3	Accrual	CFO - Net Income (NI)	CFO-NI>0
FINANCIAL LEVERAGE			
4	Equity Offering (EQ_OFFER)	Issue of common equity by the company	EQ_OFFER=0
CHANGE IN QUALITY			
PROFITABILITY			
5	Change in ROA	ROA(Year t) - ROA (Year t-1)	$\Delta ROA > 0$
OPERATING EFFICIENCY			
6	Change in EBITDA Margins	EBITDA/Sales (Year t) - EBITDA Sales (Year t-1)	Δ EBITDA Margin > 0
7	Change in Asset Turnover Ratio	Sales/Assets (Year t) - Sales/Assets (Year t-1)	Δ Asset Turnover > 0
FINANCIAL LEVERAGE			
8	Change in Net Debt to Assets (Leverage)	Net Debt/Assets (Year t) - Net Debt/Assets (Year t-1)	Δ Leverage < 0
9	Change in Current Ratio	Current Assets/Current Liabilities (Year t) – Current Assets/Current Liabilities (Year (t-1)	Δ Current Ratio > 0


**CAPITAL
PRESERVATION**

**CAPITAL
APPRECIATION**

Sector Allocation



Market Cap



Top 10 Holdings & Weights

Top 10 Portfolio Holdings	% of Net Assets
Ambuja Cements Ltd	5.0
Ashok Leyland Ltd	4.4
Bajaj Finserv Ltd	4.4
Astec Lifesciences Ltd	4.4
Federal Bank Ltd	4.3
Container Corp Of India Ltd	4.3
Apollo Hospitals Enterprise Ltd	3.9
Pidilite Industries Ltd	3.8
Info Edge India Ltd	3.7
ICICI Lombard General Insurance	3.6

Market Cap Categorization as per Average Market Capitalization of listed companies during the six months ended June 30, 2022.

Source: AMFI

Current Model Portfolio

Portfolio vs. Benchmark *(Higher Growth/ROEs with low leverage)*

PE (x)	FY22A	FY23E	FY24E	Prem/Disc to benchmark (FY24E)
NIFTY NEXT 100	38.0	26.0	21.0	22.3%
NIFTY JUNIOR	29.2	20.7	17.2	
NIFTY	24.5	21.1	17.2	

ROE (%)	FY22A	FY23E	FY24E	Prem/Disc to benchmark (FY24E)
NIFTY NEXT 100	6.8%	14.2%	15.8%	-9.9%
NIFTY JUNIOR	16.3%	17.0%	17.5%	
NIFTY	14.6%	15.6%	16.6%	

EPS growth (%)	FY22A	FY23E	FY24E	Prem/Disc to benchmark (FY24E)
NIFTY NEXT 100	18.3%	25.8%	23.7%	78.2%
NIFTY JUNIOR	21.8%	14.3%	13.3%	
NIFTY	20.4%	15.9%	17.6%	

Net Debt to Equity (%)	FY 21	Prem/Disc to benchmark
NIFTY NEXT 100	-13.8%	-22.8%
NIFTY JUNIOR	-17.9%	
NIFTY	9.1%	

* Financials excluded in calculation of D/E

Source: All ratios are based on Bloomberg consensus estimates.

Note: Premium/Discount to benchmark Nifty 500 is listed for the period FY23E.

Returns (%)	Absolute					CAGR	
	1 month	3 months	6 months	1 year	FYTD	2 Year	Since Inception (27/09/2019)
Nifty Next 100	-6.2%	-11.9%	-15.7%	-9.5%	-11.9%	20.0%	7.9%
Nifty Next 50	-6.4%	-11.2%	-13.5%	-5.2%	-11.2%	19.1%	10.4%

Disclaimer :

Past performance of any product does not indicate its future performance. The returns of investment approaches are calculated using TWRR method and considers all inflows and outflows and market value of entire portfolio for computation of performance . It is calculated net of all expenses and fees. Investment approach level performance reported above is not verified by SEBI.

Case Studies

Industry: Healthcare

- ✓ Background -Apollo Hospitals Enterprise Limited (APHS) owns and operates hospitals in India. The Company also runs a 24-hour pharmacy network via over 120 outlets across India. Apollo Hospitals also runs clinics and offer managed care and family health plans.
- ✓ Current price/Current Market Cap : Rs 3,684 / Rs. 52,963 Cr. (as of June 30, 2022)
- ✓ Price/Market Cap (at the time of purchase): Rs 1,404/ Rs. 19,448 Cr.

Secular sector: Healthcare

- Healthcare is amongst the **top outperforming sectors** in India.
- **Positive operating dynamics** – Aging population, growing middle class, Increase in lifestyle diseases and the current COVID pandemic

Use of Proprietary screeners

- **Captured by Proprietary screener**
- Strong ROE of 7%+

Fundamental Evaluation


- Matured hospitals and standalone pharmacies (50% of capital employed) are yielding ~23% ROCE and as new facilities, clinics and proton therapy center start contributing meaningfully, the consolidated ROCE trajectory of APHS can move up to 15%+ over the next two years.
- With no major bed additions in the next 2-3 years, APHS is strongly positioned to drive operational efficiencies and to ramp up occupancies at its new hospitals. APHS' leadership position in clinical outcomes and quality standards adds comfort on ramp up at new hospitals.

Valuations

- At the time at purchase, Apollo Hospitals traded at 40x P/E FY21.

Date of Investment : November 2019
 Investment Price : Rs. 1,404 per share

Current Price : Rs. 3,684 per share
 Total return (%) : 162% (2.6 yrs)



Industry: Healthcare

- ✓ Background –Divi's Laboratories Limited is one of the leading pharmaceutical companies in the contract manufacturing and pharmaceutical outsourcing market (CRAMS). Divi's strength lies in the manufacturing of leading generic compounds, nutraceutical Ingredients and custom synthesis of APIs and Intermediates for global innovator companies with a diverse therapeutic product portfolio.
- ✓ Current price/Current Market Cap : Rs 3,630 / Rs. 96,376 Cr. (as of June 30, 2022)
- ✓ Price/Market Cap (at the time of purchase): Rs.1,651/ Rs. 46,169 Cr.

Secular sector: Healthcare

- Healthcare is amongst the **top outperforming sectors** in India.
- **Positive operating dynamics** – Aging population, growing middle class, Increase in lifestyle diseases and the current COVID pandemic

Use of Proprietary screeners

- Captured by Proprietary screener
- Strong ROE of 21%+

Fundamental Evaluation

- Expect strong growth from FY22 with commercialization of planned capex and (2) Improvement in margins led by the benefits from backward integration, introduction of new technology and new machine design to reduce consumable costs. Similarly, expect EBITDA margin improvement despite incremental costs from recently/ new commissioned capacities.
- Divi's in the last phase of major capital expenditure (Rs.500 cr. to be spent in FY21). Divi's backward integration puts it ahead of the competition, which has only recently sought to reduce its China reliance.

Valuations


- At the time of purchase, Divi's Laboratories traded at 30x P/E FY21.

Divi's Laboratories Ltd



Date of Investment : October 2019
Investment Price : Rs. 1,651 per share

Current Price : Rs. 3,630 per share
Total return (%) : 120% (2.7 years)



Nifty Next 100 – Portfolio Construct



Portfolio Name	Nifty Next 100 Portfolio
Structure	Discretionary PMS
Nature	Open ended
Market cap	Multi cap
Investment Approach	The portfolio invests or proposes to invest in listed equity & equity related instruments with the aim of generating long term capital appreciation & income in the form of dividends. It can also invest in money market instruments & units of mutual fund. Features of the companies can include – High quality with consistency in growth, high ROE, low leverage & high potential for growth. Investment will be done in top 150 companies by market cap (excluding Nifty 50 companies). Stock selection is done through a combination of ‘Bottom up’ approach i.e. analyzing the fundamental attributes of the company & competition & ‘Top down’ approach i.e. analyzing the macro economic factors & industry growth characteristics
No of stocks	15-25
Investment Manager	Aditya Birla Sun Life AMC Limited (ABSLAMC)
Benchmark	Nifty Next 50
Portfolio Manager(s)	Dhaval Mehta
Tenure	Minimum 3 years
Minimum Investment	Rs. 50 lakhs
Management fee	2.5% per annum (Exclusive of Taxes)
Performance fee	Nil
Operating expenses	Please refer to Appendix A- Client Fee Schedule



A Balasubramanian, MD & CEO

- A Balasubramanian has over 29 years' experience in the Mutual Fund Industry and has been with ABSLAMC since inception. Previously worked with GIC Mutual Fund. Currently, he is on the Board of Governors of SEBI established National Institute of Securities Markets (NISM).
- He has done Diploma in Financial Management, AMP from IIM, Bangalore, MBA from GlobalNxt University, Malaysia, Advanced Management Programme from Harvard University.



Anil Shyam, Head- Alternate Business & ETF

- Anil Shyam is Head of Alternate Business at Aditya Birla Sun Life AMC Limited. He has over two decades of experience and has been associated with the organisation since October 2007.
- He has previously worked at AK Capital Services Limited, Cholamandalam AMC Limited, JM Financial Asset Management Private Limited and at ICICI Prudential AMC Limited.
- He holds a Bachelor's Degree in commerce and Master's Degree in Finance & Control from Himachal Pradesh University, Shimla.



Dhaval Mehta, Portfolio Manager (Equity)

- Has 9+ years of experience in equity research and portfolio management. Dhaval's main domain expertise is in Consumer Staples & Discretionary, Retail, Building Material, Cement and Media sector.
- Prior to joining ABSLAMC, Dhaval worked with ASK Investment Managers as Portfolio Manager. At ASK, he used to manage assets over \$200mn and have delivered stellar performance across investment cycles. Prior to ASK, he has worked with Emkay Global Financial Services, Ventura Securities and Infosys.
- Dhaval is an MBA from Narsee Monjee Institute of Management Studies Mumbai and have done its Bachelor of Engineering from D.J Sanghvi College of Engineering Mumbai.



Salvin Shah – Portfolio Manager (Equities)

- Has 9+ years in Portfolio Management and Equity Research, Salvin has extensive experience in managing Indian Equities. His endeavor is to maximize returns for the investors while keeping an eye on portfolio risk. He has been successful at identifying themes and stocks at a very early stage which has resulted in multi-bagger returns for the investors.
- Prior to joining ABSLAMC, he worked with Sanctum Wealth Management as Co-fund Manager in their PMS business. Before Sanctum, Salvin was a part of equity research team at Edelweiss Securities and Athena Investment Management.
- He is a member of Institute of Chartered Accountants of India (ICAI) and a commerce graduate from Mumbai University.

Risk Factors associated with investments in Equity & Equity related securities:

- Risk arising from the investment objective, investment strategy, asset allocation and quant model risk:
- Market risk, political and geopolitical risk and risk arising from changing business dynamics, which may affect portfolio returns. At times, portfolios of individual clients may be concentrated in certain companies/industries. The performance of the portfolios would depend on the performance of such companies / industries / sectors of the economy.
- The portfolio proposes to invest in equity and equity related securities. Equity and Equity related securities by nature are volatile and prone to price fluctuations on a daily basis due to both macro and micro factors.
- The value of the portfolio will fluctuate as the daily prices of the individual securities in which they invest fluctuate and may be worth more or less than its original cost, at a given point in time.
- In respect of investments in equity and equity-related instruments, there may be risks associated with trading volumes, settlement periods and transfer procedures that may restrict liquidity of investments in equity and equity related securities.
- The value of the portfolio may be affected generally by factors affecting securities markets, such as price and volume volatility in the capital markets, interest rates, currency exchange rates, changes in policies of the Government, taxation laws or policies of any appropriate authority and other political and economic developments and closure of stock exchanges which may have an adverse bearing on individual securities, a specific sector or all sectors including equity and debt markets.
- Within the regulatory limits applicable at any point in time, the Portfolio Manager may choose to invest in unlisted securities that offer attractive yields. Securities, which are not quoted on the stock exchanges, are inherently illiquid in nature and carry a larger amount of liquidity risk, in comparison to securities that are listed on the exchanges or offer other exit options to the investor, including a put option. This may however increase the risk of the portfolio. The liquidity and valuation of the portfolio's investments due to their holdings of unlisted securities may be affected if they have to be sold prior to their target date of disinvestments
- Investment made in unlisted equity or equity-related securities may only be realizable upon listing of these securities. Settlement problems could cause the portfolio to miss certain investment opportunities.
- Investors may note that Portfolio Manager's investment decisions may not always be profitable, as actual market movements may be at variance with anticipated trends.
- Though the constituent stocks of most indices are typically liquid, liquidity differs across stocks. Due to the heterogeneity in liquidity in the capital market segment, trades on this segment may not get implemented instantly.
- The portfolio may have higher concentration towards a particular stock or sector, at a given point in time. Any change in government policy or any other adverse development with respect to such a stock or the sector, may adversely affect the value of the portfolio.
- The portfolio also proposes to invest in derivative instruments. The Portfolio manager intends to use exchange traded derivatives as a hedging tool & does not intend to take any naked positions. Nevertheless, trading in derivatives market has risks and issues concerning the use of derivatives that investor should understand. Derivative products are specialized instruments that require investment techniques and risk analysis different from those associated with stocks and bonds.

- Derivative products are leveraged instruments and can provide disproportionate gains as well as disproportionate losses to the investor. Even a small price movement in the underlying security could have a large impact on their value. Execution of such strategies depends upon the ability of the Portfolio Manager to identify such opportunities. Identification and execution of such strategies to be persuaded by the Portfolio Manager involve uncertainty and decision of the Portfolio Manager may not always be profitable. No assurance can be given that the Portfolio Manager shall be able to identify or execute such strategies.
- The risks associated with the use of derivatives are different from or possibly greater than, the risk associated with investing directly in securities and other traditional investments. As and when the product trades in the derivatives market there are risk factors and issues concerning the use of derivatives that investors should understand. Derivative products are specialized instruments that require investment techniques and risk analysis different from those associated with stocks and bonds. The use of a derivative requires an understanding not only of the underlying instrument but also of the derivative itself.
- Derivatives require the maintenance of adequate controls to monitor the transactions entered into, the ability to assess the risk that a derivative adds to the portfolio and the ability to forecast price or interest rate movements correctly. There is a possibility that loss may be sustained by the portfolio as a result of the failure of another party (usually referred as the “counter party”) to comply with the terms of the derivatives contract. Other risks in using derivatives include the risk of mispricing or improper valuation of derivatives and the inability of derivatives to correlate perfectly with underlying assets, rates and indices. Thus, derivatives are highly leveraged instruments. Even a small price movement in the underlying security could have a large impact on their value.
- The use of a derivative requires an understanding not only of the underlying instrument but also of the derivative itself. Derivatives require the maintenance of adequate controls to monitor transactions entered into, the ability to assess the risk that a derivative adds to the portfolio and the ability to forecast price or interest rate movements correctly. There is a possibility that loss may be sustained by the portfolio as a result of the failure of another party (usually referred as the “counter party”) to comply with the terms of the derivatives contract. Derivative trades involve execution risks, whereby the rates seen on the screen may not be the rate at which ultimate execution takes place. The options buyer’s risk is limited to the premium paid, while the risk of an options writer is unlimited. However, the gains of an options writer are limited to the premiums earned. The writer of a put option bears the risk of loss if the value of the underlying asset declines below the exercise price. The writer of a call option bears a risk of loss if the value of the underlying asset increases above the exercise price. Investments in index futures face the same risk as the investments in a portfolio of shares representing an index. The extent of loss is the same as in the underlying stocks. Risk of loss in trading futures contracts can be substantial, because of the low margin deposits required, the extremely high degree of leverage involved in futures pricing and potential high volatility of the futures markets.
- The derivatives market in India is nascent and does not have the volumes that may be seen in other developed markets, which may result in volatility in the values. The Portfolio Manager may, from time to time, invest any un-deployed funds in Liquid Portfolio of PMS or in money market instruments. Though the portfolio of liquid funds comprises of short-term deposits, government securities and money market instruments, they cannot be considered as totally risk free. This is because liquidity patterns and short term interest rates of the government change, sometimes on a daily basis, thereby making the fund susceptible. Liquid Portfolio returns are not guaranteed and it entirely depends on market movements.
- Disclaimer: The views expressed above are the views of the Fund Managers of Nifty Next 100 Portfolio. They should not be construed as investment advice.
- Investments in securities are subject to market risks and there can be no assurance or guarantee that the objectives of the Product will be achieved. **Past performance may or may not be sustained in future.**
- **Regulatory Disclosure: All investors have the option to invest directly with ABSLAMC-Portfolio Manager**

To get in touch with your nearest PMS Relationship Contact Cell, visit
<https://mutualfund.adityabirlacapital.com/investor-solution-portfolio-management-service>
or
mail us at care.pms@adityabirlacapital.com
Reach us at our dedicated PMS toll free No: 1800 270 7000

Aditya Birla Sun Life Portfolio Management Services is a division of Aditya Birla Sun Life AMC Limited.

CIN no. U65991MH1994PLC080811; Website: <https://mutualfund.adityabirlacapital.com/>

One India Bulls Centre, Tower 1, 17th Floor, Jupiter Mill Compound, 841, Senapati Bapat Marg, Elphinstone Road, Mumbai - 400 013.

Tel: 4356 8000. Fax: 4356 8110 / 8111
